179 related articles for article (PubMed ID: 36840956)
1. Estimating long-term progression-free and overall survival in patients with peripheral T-cell lymphoma: A US population-based oncology simulation model based on 5-year results from the ECHELON-2 trial.
Burke JM; Yu KS; Mordi U; Bloudek B; Liu N; Phillips T
J Manag Care Spec Pharm; 2023 Mar; 29(3):314-323. PubMed ID: 36840956
[No Abstract] [Full Text] [Related]
2. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
Horwitz S; O'Connor OA; Pro B; Trümper L; Iyer S; Advani R; Bartlett NL; Christensen JH; Morschhauser F; Domingo-Domenech E; Rossi G; Kim WS; Feldman T; Menne T; Belada D; Illés Á; Tobinai K; Tsukasaki K; Yeh SP; Shustov A; Hüttmann A; Savage KJ; Yuen S; Zinzani PL; Miao H; Bunn V; Fenton K; Fanale M; Puhlmann M; Illidge T
Ann Oncol; 2022 Mar; 33(3):288-298. PubMed ID: 34921960
[TBL] [Abstract][Full Text] [Related]
3. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S; O'Connor OA; Pro B; Illidge T; Fanale M; Advani R; Bartlett NL; Christensen JH; Morschhauser F; Domingo-Domenech E; Rossi G; Kim WS; Feldman T; Lennard A; Belada D; Illés Á; Tobinai K; Tsukasaki K; Yeh SP; Shustov A; Hüttmann A; Savage KJ; Yuen S; Iyer S; Zinzani PL; Hua Z; Little M; Rao S; Woolery J; Manley T; Trümper L;
Lancet; 2019 Jan; 393(10168):229-240. PubMed ID: 30522922
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Stàhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K
J Manag Care Spec Pharm; 2023 Jul; 29(7):758-768. PubMed ID: 37404070
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada.
Zou D; Lee J; Kansal A; Ma W; Harris M; Lisano J; Fenton K; Yu KS
J Med Econ; 2022; 25(1):324-333. PubMed ID: 35172685
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of brentuximab vedotin with chemotherapy in treatment of CD30-expressing PTCL.
Feldman T; Zou D; Rebeira M; Lee J; Fanale M; Manley T; Rao S; Feliciano J; Harris M; Kansal A
Am J Manag Care; 2020 Feb; 26(2):e41-e49. PubMed ID: 32059099
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy.
Burke JM; Liu N; Yu KS; Fanale MA; Surinach A; Flores C; Lisano J; Phillips T
Oncologist; 2023 Jun; 28(6):520-530. PubMed ID: 36971492
[TBL] [Abstract][Full Text] [Related]
9. FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma.
Richardson NC; Kasamon YL; Chen H; de Claro RA; Ye J; Blumenthal GM; Farrell AT; Pazdur R
Oncologist; 2019 May; 24(5):e180-e187. PubMed ID: 30914464
[TBL] [Abstract][Full Text] [Related]
10. The clinical and economic burden of peripheral T-cell lymphoma: a systematic literature review.
Ashaye AO; Burnett H; Abogunrin S; Panchmatia H; Ovcinnikova O; Dalal M
Future Oncol; 2022 Feb; 18(4):519-535. PubMed ID: 34851173
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Huebner D; Kennedy DA; Shustov AR
J Clin Oncol; 2014 Oct; 32(28):3137-43. PubMed ID: 25135998
[TBL] [Abstract][Full Text] [Related]
12. LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
J Urol; 2023 Jul; 210(1):224-226. PubMed ID: 37119051
[TBL] [Abstract][Full Text] [Related]
13. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.
Savage KJ; Horwitz SM; Advani R; Christensen JH; Domingo-Domenech E; Rossi G; Morschhauser F; Alpdogan O; Suh C; Tobinai K; Shustov A; Trneny M; Yuen S; Zinzani PL; Trümper L; Ilidge T; O'Connor OA; Pro B; Miao H; Bunn V; Fenton K; Fanale M; Puhlmann M; Iyer S
Blood Adv; 2022 Oct; 6(19):5550-5555. PubMed ID: 35470385
[TBL] [Abstract][Full Text] [Related]
14. CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.
Newsome SD; Aliotta PJ; Bainbridge J; Bennett SE; Cutter G; Fenton K; Lublin F; Northrop D; Rintell D; Walker BD; Weigel M; Zackowski K; Jones DE
Int J MS Care; 2016; 18(6):314-323. PubMed ID: 27999526
[TBL] [Abstract][Full Text] [Related]
15. Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.
Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Uttarwar M; Lee SY; Ren H; Kennedy DA; Shustov AR
Blood; 2018 May; 131(19):2120-2124. PubMed ID: 29507077
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin in the treatment of CD30+ PTCL.
Barta SK; Gong JZ; Porcu P
Blood; 2019 Dec; 134(26):2339-2345. PubMed ID: 31697814
[TBL] [Abstract][Full Text] [Related]
17. Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma.
Dharmani C; Unni S; Pham N; Shaikh NF; Xiong Y; Vashi R; Fofah O; Strubing A; Salas M; Tu N; Wooddell M; Zhou X; Near A
Future Oncol; 2024 May; 20(15):1013-1030. PubMed ID: 37814886
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of gilteritinib for relapsed/refractory
Pandya BJ; Qi CZ; Garnham A; Yang H; Shah MV; Zeidan AM
J Manag Care Spec Pharm; 2021 Oct; 27(10):1469-1481. PubMed ID: 34595955
[No Abstract] [Full Text] [Related]
19. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
Tilly H; Morschhauser F; Sehn LH; Friedberg JW; Trněný M; Sharman JP; Herbaux C; Burke JM; Matasar M; Rai S; Izutsu K; Mehta-Shah N; Oberic L; Chauchet A; Jurczak W; Song Y; Greil R; Mykhalska L; Bergua-Burgués JM; Cheung MC; Pinto A; Shin HJ; Hapgood G; Munhoz E; Abrisqueta P; Gau JP; Hirata J; Jiang Y; Yan M; Lee C; Flowers CR; Salles G
N Engl J Med; 2022 Jan; 386(4):351-363. PubMed ID: 34904799
[TBL] [Abstract][Full Text] [Related]
20. Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD).
Hong J; Johnson WT; Kartan S; Gonsalves AS; Fenkel JM; Gong JZ; Porcu P
Curr Oncol; 2021 Dec; 28(6):5067-5072. PubMed ID: 34940065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
